Measuring sCD160 in eye fluids and blood to look for links with ischemic retinal diseases
Official title: sCD160 in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies
Run by CHU de Reims · NCT03680794 · Data updated 2026-11-12
This project tests whether sCD160 levels in the eye and blood are linked to ischemic retinal disease in adults having eye surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | CHU de Reims Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Reims) |
| Status | Recruiting |
| Started | June 27, 2018 |
| Main results expected | December 27, 2027 |
| Study ends | February 27, 2028 |
| Registry record updated | April 30, 2026 |
| Trial ID | NCT03680794 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (over 18) with social security affiliation who are scheduled for cataract or posterior-segment eye surgery and who have not had recent anti-VEGF, corticosteroid, or immunosuppressive treatments are ideal candidates.
✕Probably not a fit
People not undergoing eye surgery, those with recent anti-VEGF/steroid/immunosuppressive treatments, active systemic or ocular inflammation, or CRP > 10 mg/mL are unlikely to participate or benefit from the results.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will recruit 120 adults undergoing cataract or posterior-segment surgery at CHU Reims and collect aqueous or vitreous samples plus a blood sample at the start of surgery. sCD160 concentrations will be measured by ELISA in triplicate, and a panel of ischemia-related biomarkers will be measured in vitreous by Luminex. The main goal is to compare sCD160 levels between patients with and without ischemic retinopathies (including diabetic retinopathy and retinal vein occlusion) and to explore correlations between ocular and serum sCD160 and other biomarkers. Patients with recent anti-VEGF, steroid, or immunosuppressive treatments, active inflammation, or certain prior ocular surgeries are excluded to avoid confounding.
Why it matters
Potential benefit: If successful, sCD160 measurement could become a biomarker to help identify or monitor ischemic retinal disease and point toward new therapeutic approaches targeting the CD160 pathway.
How similar studies have gone: Preclinical work shows anti-CD160 antibodies can reduce angiogenesis and sCD160 has been reported elevated in severe diabetic retinopathy, but clinical evidence directly linking sCD160 concentrations to ischemic retinopathies is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
inclusion criteria : * over 18 years old * with social security affiliation * willing to participate this study non-inclusion criteria : * any prior (3 months) or concomitant treatment with anti-VEGF therapy, corticosteroids, or immunosuppressive agents * any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma, severe intraocular, periocular infection, inflammation, or radiation * any serious allergy to the fluorescein sodium for injection in angiography * any history of previous systemic anti-VEGF treatment * any history of inflammatory or auto-immune disease * any active extraocular inflammation or infection in the last 4 weeks before surgery exclusion criteria : * Patients with C-reactive protein CRP \> 10mg/mL (serum sampling during surgery)
Where it's running
-
Chu Reims
Reims, France Recruiting
Study contacts
- Study coordinator: Carl ARNDT
- Email: carndt@chu-reims.fr
- Phone: 326787090
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Watching a short video before anti-VEGF eye injections
This trial will test whether watching a brief procedural video before a first anti-VEGF intravitreal injection helps people with retinal diseases feel less anxious and have fewer or smaller subconjunctival hemorrhages.
-
Using advanced imaging to analyze retinal vascular diseases
This study is testing new imaging techniques to see how they can help doctors understand and track the progress of retinal diseases like diabetic retinopathy in both healthy people and those affected by these conditions.
-
MB-102 versus fluorescein sodium for retinal angiography imaging
This trial will test whether the new dye MB-102 produces safe, high-quality retinal angiography images in adults with healthy eyes or retinal vascular disease compared with standard fluorescein sodium.
-
Biorepository for studying retinal diseases
This study is collecting health information and samples from people with and without eye diseases to see how these conditions develop and respond to treatments.
-
Corticosteroid for Diabetic Macular Edema (DME) in Adults with Diabetic Retinopathy
This trial tests whether intravitreal corticosteroid injections can influence inflammatory biomarkers and improve DME in adults with type 2 diabetes.
-
Automated detection of diabetic retinopathy lesions in fundus photos
This study tests a smart imaging system within the DDART device to see if it can reliably spot diabetic retinopathy lesions in color fundus photographs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.